FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093139684> ?p ?o ?g. }

• W3093139684 abstract "The Cystic Fibrosis Foundation recommends both short-term and long-acting insulin therapy when cystic fibrosis-related diabetes (CFRD) has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/L (125 mg/dL); or oral glucose tolerance tests greater than 11.11 mmol/L (200 mg/dL) at two hours; or symptomatic diabetes for random glucose levels greater than 11.11 mmol/L (200 mg/dL); or glycated hemoglobin levels of at least 6.5%. This is an update of a previously published review.To establish the effectiveness of insulin and oral agents for managing diabetes in people with cystic fibrosis in relation to blood sugar levels, lung function and weight management.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also handsearched abstracts from pulmonary symposia and the North American Cystic Fibrosis Conferences. Date of most recent register search: 10 September 2020. We searched online trials registries; date of most recent searches: 21 March 2020.Randomized controlled trials comparing all methods of pharmacological diabetes therapy in people with diagnosed CFRD.Two authors independently extracted data and assessed the risk of bias in the included studies. Authors also used GRADE to assess the quality of the evidence.The searches identified 29 trials (45 references). Four included trials provide results: one short-term single-center cross-over trial (seven adults) comparing insulin with oral repaglinide and no medication in adults with CFRD and normal fasting glucose; one long-term multicenter trial (61 adults with CFRD) comparing insulin with oral repaglinide and placebo; one long-term multicenter trial (67 adults) comparing insulin with oral repaglinide; and one 12-week single-center cross-over trial (20 adults) comparing the long-acting insulin glargine to short-term neutral protamine Hagedorn insulin. Two ongoing trials of newly approved incretin mimics have been noted for possible future inclusion. Downgrading of the quality of the evidence was mainly due to risks of bias across all domains, but particularly due to concerns surrounding allocation concealment and selective reporting. There were also some concerns due to imprecision from small sample sizes and low event rates. Finally, there may be some bias due to the amounts of insulin and repaglinide given not being comparable. Data from one trial comparing insulin to placebo (39 participants) did not show any difference between groups for the primary outcomes of blood glucose levels (very low-quality evidence), lung function (low-quality evidence) or nutritional status (low-quality evidence). Similarly, no differences between groups were seen for the secondary outcomes of number of hypoglycemic episodes (low-quality evidence), secondary infection complications or quality of life (QoL). These results were mirrored in the narrative reports for the second trial in this comparison (seven participants). Data from the one-year trial comparing repaglinide to placebo (38 participants), showed no differences between groups for the primary outcomes of blood glucose levels (very low-quality evidence), lung function (low-quality evidence) and nutritional status (low-quality evidence). Also, no differences were seen between groups for the secondary outcomes of number of hypoglycemic episodes (low-quality evidence), secondary infection complications or QoL. These findings were mirrored in the narrative reports for the second trial (n = 7) in this comparison. Three trials compared insulin to repaglinide (119 participants). Data from one trial (n = 67) showed no difference in blood glucose levels at either 12 months (high-quality evidence) or 24 months; narrative reports from one trial (45 participants) reported no difference between groups, but the second trial (7 participants) reported a beneficial effect of insulin over repaglinide. Two trials (112 participants) found no difference between insulin and repaglinide in lung function or nutritional status (moderate-quality evidence). Two trials (56 participants) reported no difference in the number of hypoglycemic episodes (low-quality evidence). One trial (45 participants) reported no difference between groups in secondary infections and cystic fibrosis QoL. The single trial comparing glargine to neutral protamine Hagedorn insulin did not report directly on the review's primary outcomes, but did report no differences between groups in post-prandial glucose values and weight; neither group reported infectious complications. There was no difference in episodes of hypoglycemia (very low-quality evidence) and while there was no difference reported in QoL, all participants opted to continue treatment with glargine after the trial was completed. Mortality was not reported by any trial in any comparison, but death was not given as a reason for withdrawal in any trial.This review has not found any conclusive evidence that any agent has a distinct advantage over another in controlling hyperglycemia or the clinical outcomes associated with CFRD. Given the treatment burden already experienced by people with cystic fibrosis, oral therapy may be a viable treatment option. While some cystic fibrosis centers use oral medications to help control diabetes, the Cystic Fibrosis Foundation (USA) clinical practice guidelines support the use of insulin therapy and this remains the most widely-used treatment method. Randomized controlled trials specifically related to controlling diabetes and its impact on the course of pulmonary disease process in cystic fibrosis continue to be a high priority. Specifically, investigators should evaluate adherence to different therapies and also whether there is benefit in using additional hypoglycemic agents as well as the newly approved incretin mimics. Agents that potentiate insulin action, especially agents with additional anti-inflammatory potential should also be further investigated as adjuvant therapy to insulin." @default.
• W3093139684 created "2020-10-22" @default.
• W3093139684 creator A5049272863 @default.
• W3093139684 creator A5053151818 @default.
• W3093139684 date "2020-10-19" @default.
• W3093139684 modified "2023-10-16" @default.
• W3093139684 title "Drug treatments for managing cystic fibrosis-related diabetes" @default.
• W3093139684 cites W1626102637 @default.
• W3093139684 cites W1867385492 @default.
• W3093139684 cites W1972306903 @default.
• W3093139684 cites W1974173049 @default.
• W3093139684 cites W1981362726 @default.
• W3093139684 cites W1981440346 @default.
• W3093139684 cites W1982804090 @default.
• W3093139684 cites W1983818979 @default.
• W3093139684 cites W1990621740 @default.
• W3093139684 cites W1997290633 @default.
• W3093139684 cites W2030008539 @default.
• W3093139684 cites W2032314339 @default.
• W3093139684 cites W2032595821 @default.
• W3093139684 cites W2036666726 @default.
• W3093139684 cites W2042399870 @default.
• W3093139684 cites W2043356279 @default.
• W3093139684 cites W2053220154 @default.
• W3093139684 cites W2065536320 @default.
• W3093139684 cites W2080318972 @default.
• W3093139684 cites W2082563297 @default.
• W3093139684 cites W2090854614 @default.
• W3093139684 cites W2094312349 @default.
• W3093139684 cites W2101102093 @default.
• W3093139684 cites W2103455150 @default.
• W3093139684 cites W2109801094 @default.
• W3093139684 cites W2117417969 @default.
• W3093139684 cites W2125435699 @default.
• W3093139684 cites W2125761431 @default.
• W3093139684 cites W2126604555 @default.
• W3093139684 cites W2130235475 @default.
• W3093139684 cites W2147194341 @default.
• W3093139684 cites W2151174404 @default.
• W3093139684 cites W2151909715 @default.
• W3093139684 cites W2152397772 @default.
• W3093139684 cites W2157245356 @default.
• W3093139684 cites W2157745572 @default.
• W3093139684 cites W2161389068 @default.
• W3093139684 cites W2168758941 @default.
• W3093139684 cites W2286093658 @default.
• W3093139684 cites W2324736494 @default.
• W3093139684 cites W2414977694 @default.
• W3093139684 cites W2522617936 @default.
• W3093139684 cites W2624674854 @default.
• W3093139684 cites W2735025144 @default.
• W3093139684 cites W2775772713 @default.
• W3093139684 cites W2807014976 @default.
• W3093139684 cites W2808961778 @default.
• W3093139684 cites W2893678371 @default.
• W3093139684 cites W2937933783 @default.
• W3093139684 cites W4213243604 @default.
• W3093139684 cites W4243237697 @default.
• W3093139684 cites W4253700141 @default.
• W3093139684 cites W4284714303 @default.
• W3093139684 doi "https://doi.org/10.1002/14651858.cd004730.pub5" @default.
• W3093139684 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8094754" @default.
• W3093139684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33075159" @default.
• W3093139684 hasPublicationYear "2020" @default.
• W3093139684 type Work @default.
• W3093139684 sameAs 3093139684 @default.
• W3093139684 citedByCount "7" @default.
• W3093139684 countsByYear W30931396842021 @default.
• W3093139684 countsByYear W30931396842022 @default.
• W3093139684 countsByYear W30931396842023 @default.
• W3093139684 crossrefType "journal-article" @default.
• W3093139684 hasAuthorship W3093139684A5049272863 @default.
• W3093139684 hasAuthorship W3093139684A5053151818 @default.
• W3093139684 hasBestOaLocation W30931396842 @default.
• W3093139684 hasConcept C126322002 @default.
• W3093139684 hasConcept C134018914 @default.
• W3093139684 hasConcept C168563851 @default.
• W3093139684 hasConcept C2776938444 @default.
• W3093139684 hasConcept C2777180221 @default.
• W3093139684 hasConcept C2777391703 @default.
• W3093139684 hasConcept C2777538456 @default.
• W3093139684 hasConcept C2779306644 @default.
• W3093139684 hasConcept C2780520431 @default.
• W3093139684 hasConcept C2780609358 @default.
• W3093139684 hasConcept C535046627 @default.
• W3093139684 hasConcept C555293320 @default.
• W3093139684 hasConcept C71924100 @default.
• W3093139684 hasConcept C90924648 @default.
• W3093139684 hasConceptScore W3093139684C126322002 @default.
• W3093139684 hasConceptScore W3093139684C134018914 @default.
• W3093139684 hasConceptScore W3093139684C168563851 @default.
• W3093139684 hasConceptScore W3093139684C2776938444 @default.
• W3093139684 hasConceptScore W3093139684C2777180221 @default.
• W3093139684 hasConceptScore W3093139684C2777391703 @default.
• W3093139684 hasConceptScore W3093139684C2777538456 @default.
• W3093139684 hasConceptScore W3093139684C2779306644 @default.
• W3093139684 hasConceptScore W3093139684C2780520431 @default.
• W3093139684 hasConceptScore W3093139684C2780609358 @default.
• W3093139684 hasConceptScore W3093139684C535046627 @default.
• W3093139684 hasConceptScore W3093139684C555293320 @default.

• next